Clinical trials: Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy
Certain percent of the eyes with proliferative diabetic retinopathymay require pars plana vitrectomy (PPV) due to vitreous haemorrhage, proliferative membrane, and tractional retinal detachment.
- Trial name
- NCT02857491
- Testing
- ranibizumab, pars plana vitrectomy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
Severe Non-proliferative Diabetic Retinopathy
Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR
This randomized, parallel controlled, clinical-trial aims to evaluate the therapeutic efficacy of 532nm laser partially subthreshold panretinal photocoagulation with PASCAL endpoint management function for severe…
- Trial name
- S-PRP (NCT01759121)
- Testing
- T-PRP, S-PRP
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Proliferative Diabetic Retinopathy
PRP vs Bevacizumab for PDR Treatment
Protocol S by DRCR.net has shown that receive Ranibizumab as anti-vascular endothelial growth factor (anti-VEGF) therapy with deferred panretinal photocoagulation (PRP) are non-inferior to those in eyes that receive standard…
- Trial name
- NCT02705274
- Testing
- Bevacizumab, Panretinal photocoagulation
- Where
- Syria
- Volunteers
- 30 people
- Sponsor
- Marashi Eye Clinic
Proliferative Diabetic Retinopathy (PDR)
A Study Assessing Efficacy and Safety of OC-10X in the Treatment of PDR
The present study is intended to evaluate the efficacy and safety of topical OC-10X Ophthalmic Suspension in patients diagnosed with proliferative diabetic retinopathy (level 61, 65, 71, or 75). OcuCure Therapeutics, Inc.
- Trial name
- NCT02735369
- Testing
- 2% OC-10X
- Where
- Bangladesh
- Volunteers
- 40 people
- Sponsor
- OcuCure Therapeutics, Inc.
Proliferative Diabetic Retinopathy
Propranolol for Diabetic Retinopathy
This study is investigating if the oral beta antagonist propranolol can induce regression of retinal neovascularization associated with proliferative diabetic retinopathy.
- Trial name
- NCT01535495
- Testing
- Propranolol
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Wisconsin, Madison
Non-proliferative Diabetic Retinopathy
Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy
The purpose of this study is to evaluate the efficacy and safety of Compound Danshen Dripping Pills in patients with diabetic retinopathy(Syndrome Of Qi-Stagnation and Blood Stasis).
- Trial name
- NCT02388984
- Testing
- Compound danshen dripping pills
- Where
- 16 sites in China
- Volunteers
- 480 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Proliferative Diabetic Retinopathy, Macular Degeneration
Analysis of Aqueous and Vitreous Humor
Clinical Retina research studies often collect aqueous samples in hopes of estimating levels of drug or cytokines in the vitreous. Little is known about how well vitreous and aqueous correlate.
- Conditions
- Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma
- Trial name
- ARK (NCT02067013)
- Testing
- Ranibizumab, No Ranibizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- California Retina Consultants
Diabetic Non-proliferative Retinopathy, Type2 Diabetes
Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy
This study include 384 Participants with diabetic non-proliferative retinopathy Design Method: Randomized, double blind, placebo controlled and multicenter clinical study.
- Trial name
- NCT03025399
- Testing
- Tangwang prescription
- Volunteers
- 384 people
- Sponsor
- Fengmei Lian
Proliferative Diabetic Retinopathy - High Risk
Patient Comfort Using Green vs. Yellow Pan Retinal Photocoagulation
Our aim is to compare patient comfort when using the 532 nanometer (green) wavelength laser to the 577 nanometer (yellow) wavelength laser during pan retinal photocoagulation to treat patients with diabetic retinopathy.
- Trial name
- NCT02995629
- Testing
- laser indirect ophthalmoscopy pan retinal photocoagulation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wills Eye
Proliferative Diabetic Retinopathy
Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH
This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days but >7 days prior to vitrectomy and one intraoperative IAI at…
- Trial name
- LASERLESS (NCT02976012)
- Testing
- Aflibercept, Endolaserless Vitrectomy
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment.
- Trial name
- LRTforDME+PRP (NCT00445003)
- Testing
- Ranibizumab, Triamcinolone Acetonide, Focal/grid laser
- Where
- 56 sites in United States
- Volunteers
- 333 people
- Sponsor
- Jaeb Center for Health Research
Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eyes presenting with vitreous hemorrhage…
- Trial name
- N (NCT00996437)
- Testing
- Ranibizumab, Saline
- Where
- 67 sites in United States
- Volunteers
- 261 people
- Sponsor
- Jaeb Center for Health Research
Proliferative Diabetic Retinopathy
25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China
Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR.
- Trial name
- RaTAPDR (NCT02328118)
- Testing
- Ranibizumab, Triamcinolone Acetonide
- Where
- China
- Volunteers
- 120 people
- Sponsor
- JUNYAN ZHANG
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research
Proliferative Diabetic Retinopathy
Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study
To assess the safety of intravitreal aflibercept injection in the treatment of proliferative diabetic retinopathy (PDR) by evaluating the incidence and severity of adverse events.
- Trial name
- ACT (NCT01813773)
- Testing
- Intravitreal Aflibercept Injection (IAI)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ophthalmic Consultants of Long Island
Epiretinal Membrane, Macular Hole
Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy
The aim of this study is to test the efficacy of the combination of dye Lutein, Zeaxanthin and brilliant blue to stain the internal limiting membrane as well as the epiretinal membranes during the Vitrectomy surgery.
- Conditions
- Epiretinal Membrane, Macular Hole, Proliferative Diabetic Retinopathy
- Trial name
- NCT01627977
- Testing
- Dye of Lutein, Zeaxanthin and Brilliant Blue
- Where
- Brazil
- Volunteers
- 18 people
- Sponsor
- Federal University of São Paulo
Proliferative Diabetic Retinopathy (PDR)
Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X
The present study is intended to evaluate the safety and tolerability of topical OC-10X Ophthalmic Suspension in healthy human subjects. OcuCure Therapeutics, Inc.
- Trial name
- NCT01869933
- Testing
- OC-10X
- Where
- Bangladesh
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- OcuCure Therapeutics, Inc.
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy
The purpose of this study is to determine the effect of pre- and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy.
- Trial name
- IBDV (NCT00745498)
- Testing
- Bevacizumab
- Where
- South Korea
- Volunteers
- 126 people
- Sponsor
- Seoul National University Bundang Hospital
Proliferative Diabetic Retinopathy
Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN
To assess the safety and efficacy of intravitreal aflibercept injection in the regression of retinal neovascularization secondary to high-risk PDR.
- Trial name
- ELYSIAN (NCT02630277)
- Testing
- Aflibercept
- Volunteers
- 30 people
- Sponsor
- Valley Retina Institute